TY - JOUR T1 - Hypoxia-inducible Factor-1α Suppression in Ovarian Clear-cell Carcinoma Cells by Silibinin Administration JF - Anticancer Research JO - Anticancer Res SP - 6791 LP - 6798 DO - 10.21873/anticanres.14702 VL - 40 IS - 12 AU - MARIKO MIYAZAWA AU - MASANORI YASUDA AU - MASAKI MIYAZAWA AU - NAOKI OGANE AU - TOMOMI KATOH AU - MITSUTAKE YANO AU - TAKESHI HIRASAWA AU - MIKIO MIKAMI AU - HITOSHI ISHIMOTO Y1 - 2020/12/01 UR - http://ar.iiarjournals.org/content/40/12/6791.abstract N2 - Background/Aim: Advanced ovarian clear-cell carcinoma (CCC) fails to respond to standard chemotherapy, and has a poor prognosis. Since hypoxia-inducible factor-1 (HIF-1) stimulates various genes involved in cancer, we aimed to examine the efficacy of silibinin, an active component of milk thistle belonging to Asteraceae, in suppressing HIF-1 activity, and elucidate the underlying mechanism in human CCC cell lines. Materials and Methods: Human ovarian CCC cell lines HAC-2, OVISE, and RMG-1 were treated with 500 μM silibinin for 4 h under normoxic and hypoxic conditions. Using DNA microarray, we analysed genes whose expression modulated more than 2-fold in response to hypoxia, whereas HIF-1α expression was measured using ELISA. Results: Silibinin treatment decreased HIF-1α protein in all cell lines, and eIF4E2 and RPS6 mRNA in HAC-2 and RMG-1 cells. Conclusion: Silibinin suppressed HIF-1α protein under hypoxic conditions in CCC cell lines and could be a potential anti-cancer drug. ER -